Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH-120 Nasal Spray for Post-exposure Prophylaxis of SARS-CoV-2
NCT05787418Phase 3Completed
- Sponsor
- Huahui Health
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HH-120 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Huahui Health. Primary endpoint: Incidence of symptomatic SARS-CoV-2 infection at 7 days. Started Mar 2023; status: completed.
02
Drugs
HH-120
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05787418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05787418.